Licensing · MENA · Announced 26 Oct 2026
Autotelic Bio → Menarini
Korean biotech Autotelic Bio has licensed Middle East rights for ATB-101 — the world’s first hypertension-plus-diabetes combination pill — to Menarini, its third regional champion deal after Mexico’s Chinoin and Brazil’s Aché.
Parties: Autotelic Bio (South Korea) → Menarini (Italy)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Middle East
- Therapeutic area
- Cardiovascular
- Asset
- ATB-101 — world’s first fixed-dose combination of olmesartan + dapagliflozin for simultaneous treatment of hypertension and type 2 diabetes; exclusive Middle East rights
- Announced
- 26 Oct 2026
Our analysis
Why this matters
A Korean biotech with $18 million raised has out-licensed its lead asset to three regional champions on three continents in twenty-eight months — and the newest is Menarini, for the Middle East. ATB-101, the world's first olmesartan-plus-dapagliflozin single pill for patients with both hypertension and type 2 diabetes, follows the same playbook Autotelic used in Mexico (Chinoin, 2024) and Brazil (Aché, 2025): exclusive rights to a dominant local player, milestones plus royalties, zero own commercial infrastructure.
For CEOs: the Gulf's hypertension-diabetes comorbidity burden is among the world's highest, and single-pill adherence products are exactly what regional chronic-disease programs want on formulary. For BD: this is the third consecutive quarter that a small originator has skipped Big Pharma and licensed directly to a MENA regional champion.
The full analysis is free to read with a work email on this page.